Search
Targeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read moreT2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
7th European CAR T-cell Meeting
The European Hematology Association (EHA) and the EBMT are excited to announce the 7th edition of the jointly organized European CAR T-cell Meeting.
Read morePublications
The EBMT/EHA CAR-T Cell Handbook
Editors: Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele. 2022, ISBN 978-3-030-94352-3 ISBN 978-3-030-94353-0 (eBook).
EHA-EBMT 2nd European CAR T Cell Meeting
Dates: January 30 – February 1, 2020
Location: Sitges (Barcelona), Spain
Chairs: H Einsele, C Chabannon
The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…
Uptake of CAR T cell therapy in Europe
Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.
Read moreSickle Cell Disease: From Research to Clinical Management
Elevate your expertise and impact patient care by joining the EHA's pilot preceptorship on Sickle Cell Disease, designed for early-career hematology specialists, clinicians, lab technicians, and pathologists.
Read more